Adjuvant treatment with osteoconductive agents in a canine model of hip reconstruction

D. A. Chakkalakal, J. Redepenning, Kevin Lloyd Garvin, Jr Quigley, J. R. Novak, E. D. Fritz, T. J. Mollner, D. L. Puls, M. H. McGuire

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We used a canine model of hip reconstruction to determine whether adjuvant treatment with two osteoconductive agents would enhance bone ingrowth into the porous surface of the prosthesis and the bonding strength of prosthesis to femur. Canine femoral prostheses were coated with 0.9% saline (control), with hydroxyapatite using a new room-temperature electrolytic method, or with chitosan, a linear polysaccharide obtained by partial deacetylation of chitin, and implanted in the right femora of adult mongrel dogs. The dogs were euthanized at either 6 weeks or 6 months and the femur-prosthesis composite was sectioned transversely. Bonding strength was determined by push-out tests on two sections per dog, histology and bone ingrowth (by scanning electron microscopy in the back-scattered electron mode) in adjacent sections, and changes in the host femur by contact radiography of other sections. The main findings in this study were as follows: Compared to controls at 6 weeks, the available pore volume occupied by bone (bone volume) was increased by chitosan treatment (45%, p < 0.0003), but not by the hydroxyapatite treatment. The highest average bone volume (75.6 ± 9.2%) was for the chitosan group, whereas the highest bonding strength (1049 ± 521 N) was for the hydroxyapatite group, at 6 months. Approximately 86% of the bone volume in the latter at 6 months was already attained in the chitosan group at 6 weeks. Histologically, chitosan treatment appears to have produced more volume of immature bone and fibrous tissue quickly, whereas mostly mature bone was produced slowly by hydroxyapatite treatment. Bonding strengths were not significantly different from controls because of variability due to the presence of fibrous tissue (chitosan, 6 weeks), inadequate bone ingrowth (hydroxyapatite, 6 weeks), or small sample size (6 months). We hypothesize that bonding strength may be enhanced further by using chitosan and hydroxyapatite as vehicles for coating prostheses with osteoinductive factors.

Original languageEnglish (US)
Pages (from-to)176-187
Number of pages12
JournalEuropean Journal of Experimental Musculoskeletal Research
Volume4
Issue number3-4
StatePublished - Dec 1 1995

Fingerprint

Chitosan
Canidae
Hip
Durapatite
Bone and Bones
Prostheses and Implants
Femur
Dogs
Therapeutics
Chitin
Thigh
Radiography
Electron Scanning Microscopy
Sample Size
Polysaccharides
Histology
Electrons
Temperature

Keywords

  • bonding strength
  • bone ingrowth
  • bone remodeling
  • cementless arthroplasty
  • chitosan
  • femoral prosthesis
  • hydroxyapatite

ASJC Scopus subject areas

  • Biophysics
  • Rheumatology
  • Surgery

Cite this

Chakkalakal, D. A., Redepenning, J., Garvin, K. L., Quigley, J., Novak, J. R., Fritz, E. D., ... McGuire, M. H. (1995). Adjuvant treatment with osteoconductive agents in a canine model of hip reconstruction. European Journal of Experimental Musculoskeletal Research, 4(3-4), 176-187.

Adjuvant treatment with osteoconductive agents in a canine model of hip reconstruction. / Chakkalakal, D. A.; Redepenning, J.; Garvin, Kevin Lloyd; Quigley, Jr; Novak, J. R.; Fritz, E. D.; Mollner, T. J.; Puls, D. L.; McGuire, M. H.

In: European Journal of Experimental Musculoskeletal Research, Vol. 4, No. 3-4, 01.12.1995, p. 176-187.

Research output: Contribution to journalArticle

Chakkalakal, DA, Redepenning, J, Garvin, KL, Quigley, J, Novak, JR, Fritz, ED, Mollner, TJ, Puls, DL & McGuire, MH 1995, 'Adjuvant treatment with osteoconductive agents in a canine model of hip reconstruction', European Journal of Experimental Musculoskeletal Research, vol. 4, no. 3-4, pp. 176-187.
Chakkalakal, D. A. ; Redepenning, J. ; Garvin, Kevin Lloyd ; Quigley, Jr ; Novak, J. R. ; Fritz, E. D. ; Mollner, T. J. ; Puls, D. L. ; McGuire, M. H. / Adjuvant treatment with osteoconductive agents in a canine model of hip reconstruction. In: European Journal of Experimental Musculoskeletal Research. 1995 ; Vol. 4, No. 3-4. pp. 176-187.
@article{936930062d4f47d8a85274d1a3394405,
title = "Adjuvant treatment with osteoconductive agents in a canine model of hip reconstruction",
abstract = "We used a canine model of hip reconstruction to determine whether adjuvant treatment with two osteoconductive agents would enhance bone ingrowth into the porous surface of the prosthesis and the bonding strength of prosthesis to femur. Canine femoral prostheses were coated with 0.9{\%} saline (control), with hydroxyapatite using a new room-temperature electrolytic method, or with chitosan, a linear polysaccharide obtained by partial deacetylation of chitin, and implanted in the right femora of adult mongrel dogs. The dogs were euthanized at either 6 weeks or 6 months and the femur-prosthesis composite was sectioned transversely. Bonding strength was determined by push-out tests on two sections per dog, histology and bone ingrowth (by scanning electron microscopy in the back-scattered electron mode) in adjacent sections, and changes in the host femur by contact radiography of other sections. The main findings in this study were as follows: Compared to controls at 6 weeks, the available pore volume occupied by bone (bone volume) was increased by chitosan treatment (45{\%}, p < 0.0003), but not by the hydroxyapatite treatment. The highest average bone volume (75.6 ± 9.2{\%}) was for the chitosan group, whereas the highest bonding strength (1049 ± 521 N) was for the hydroxyapatite group, at 6 months. Approximately 86{\%} of the bone volume in the latter at 6 months was already attained in the chitosan group at 6 weeks. Histologically, chitosan treatment appears to have produced more volume of immature bone and fibrous tissue quickly, whereas mostly mature bone was produced slowly by hydroxyapatite treatment. Bonding strengths were not significantly different from controls because of variability due to the presence of fibrous tissue (chitosan, 6 weeks), inadequate bone ingrowth (hydroxyapatite, 6 weeks), or small sample size (6 months). We hypothesize that bonding strength may be enhanced further by using chitosan and hydroxyapatite as vehicles for coating prostheses with osteoinductive factors.",
keywords = "bonding strength, bone ingrowth, bone remodeling, cementless arthroplasty, chitosan, femoral prosthesis, hydroxyapatite",
author = "Chakkalakal, {D. A.} and J. Redepenning and Garvin, {Kevin Lloyd} and Jr Quigley and Novak, {J. R.} and Fritz, {E. D.} and Mollner, {T. J.} and Puls, {D. L.} and McGuire, {M. H.}",
year = "1995",
month = "12",
day = "1",
language = "English (US)",
volume = "4",
pages = "176--187",
journal = "European Journal of Experimental Musculoskeletal Research",
issn = "0803-5288",
number = "3-4",

}

TY - JOUR

T1 - Adjuvant treatment with osteoconductive agents in a canine model of hip reconstruction

AU - Chakkalakal, D. A.

AU - Redepenning, J.

AU - Garvin, Kevin Lloyd

AU - Quigley, Jr

AU - Novak, J. R.

AU - Fritz, E. D.

AU - Mollner, T. J.

AU - Puls, D. L.

AU - McGuire, M. H.

PY - 1995/12/1

Y1 - 1995/12/1

N2 - We used a canine model of hip reconstruction to determine whether adjuvant treatment with two osteoconductive agents would enhance bone ingrowth into the porous surface of the prosthesis and the bonding strength of prosthesis to femur. Canine femoral prostheses were coated with 0.9% saline (control), with hydroxyapatite using a new room-temperature electrolytic method, or with chitosan, a linear polysaccharide obtained by partial deacetylation of chitin, and implanted in the right femora of adult mongrel dogs. The dogs were euthanized at either 6 weeks or 6 months and the femur-prosthesis composite was sectioned transversely. Bonding strength was determined by push-out tests on two sections per dog, histology and bone ingrowth (by scanning electron microscopy in the back-scattered electron mode) in adjacent sections, and changes in the host femur by contact radiography of other sections. The main findings in this study were as follows: Compared to controls at 6 weeks, the available pore volume occupied by bone (bone volume) was increased by chitosan treatment (45%, p < 0.0003), but not by the hydroxyapatite treatment. The highest average bone volume (75.6 ± 9.2%) was for the chitosan group, whereas the highest bonding strength (1049 ± 521 N) was for the hydroxyapatite group, at 6 months. Approximately 86% of the bone volume in the latter at 6 months was already attained in the chitosan group at 6 weeks. Histologically, chitosan treatment appears to have produced more volume of immature bone and fibrous tissue quickly, whereas mostly mature bone was produced slowly by hydroxyapatite treatment. Bonding strengths were not significantly different from controls because of variability due to the presence of fibrous tissue (chitosan, 6 weeks), inadequate bone ingrowth (hydroxyapatite, 6 weeks), or small sample size (6 months). We hypothesize that bonding strength may be enhanced further by using chitosan and hydroxyapatite as vehicles for coating prostheses with osteoinductive factors.

AB - We used a canine model of hip reconstruction to determine whether adjuvant treatment with two osteoconductive agents would enhance bone ingrowth into the porous surface of the prosthesis and the bonding strength of prosthesis to femur. Canine femoral prostheses were coated with 0.9% saline (control), with hydroxyapatite using a new room-temperature electrolytic method, or with chitosan, a linear polysaccharide obtained by partial deacetylation of chitin, and implanted in the right femora of adult mongrel dogs. The dogs were euthanized at either 6 weeks or 6 months and the femur-prosthesis composite was sectioned transversely. Bonding strength was determined by push-out tests on two sections per dog, histology and bone ingrowth (by scanning electron microscopy in the back-scattered electron mode) in adjacent sections, and changes in the host femur by contact radiography of other sections. The main findings in this study were as follows: Compared to controls at 6 weeks, the available pore volume occupied by bone (bone volume) was increased by chitosan treatment (45%, p < 0.0003), but not by the hydroxyapatite treatment. The highest average bone volume (75.6 ± 9.2%) was for the chitosan group, whereas the highest bonding strength (1049 ± 521 N) was for the hydroxyapatite group, at 6 months. Approximately 86% of the bone volume in the latter at 6 months was already attained in the chitosan group at 6 weeks. Histologically, chitosan treatment appears to have produced more volume of immature bone and fibrous tissue quickly, whereas mostly mature bone was produced slowly by hydroxyapatite treatment. Bonding strengths were not significantly different from controls because of variability due to the presence of fibrous tissue (chitosan, 6 weeks), inadequate bone ingrowth (hydroxyapatite, 6 weeks), or small sample size (6 months). We hypothesize that bonding strength may be enhanced further by using chitosan and hydroxyapatite as vehicles for coating prostheses with osteoinductive factors.

KW - bonding strength

KW - bone ingrowth

KW - bone remodeling

KW - cementless arthroplasty

KW - chitosan

KW - femoral prosthesis

KW - hydroxyapatite

UR - http://www.scopus.com/inward/record.url?scp=0029432132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029432132&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 176

EP - 187

JO - European Journal of Experimental Musculoskeletal Research

JF - European Journal of Experimental Musculoskeletal Research

SN - 0803-5288

IS - 3-4

ER -